Targeting C-reactive protein for the treatment of cardiovascular disease.
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Complement-mediated inflammation exacerbates the tissue injury of ischaemic necrosis in heart attacks and strokes, the most common causes of death in developed countries. Large infarct size increases immediate morbidity and mortality and, in survivors of the acute event, larger non-functional scars adversely affect long-term prognosis. There is thus an important unmet medical need for new cardioprotective and neuroprotective treatments. We have previously shown that human C-reactive protein (CRP), the classical acute-phase protein that binds to ligands exposed in damaged tissue and then activates complement, increases myocardial and cerebral infarct size in rats subjected to coronary or cerebral artery ligation, respectively. Rat CRP does not activate rat complement, whereas human CRP activates both rat and human complement. Administration of human CRP to rats is thus an excellent model for the actions of endogenous human CRP. Here we report the design, synthesis and efficacy of 1,6-bis(phosphocholine)-hexane as a specific small-molecule inhibitor of CRP. Five molecules of this palindromic compound are bound by two pentameric CRP molecules, crosslinking and occluding the ligand-binding B-face of CRP and blocking its functions. Administration of 1,6-bis(phosphocholine)-hexane to rats undergoing acute myocardial infarction abrogated the increase in infarct size and cardiac dysfunction produced by injection of human CRP. Therapeutic inhibition of CRP is thus a promising new approach to cardioprotection in acute myocardial infarction, and may also provide neuroprotection in stroke. Potential wider applications include other inflammatory, infective and tissue-damaging conditions characterized by increased CRP production, in which binding of CRP to exposed ligands in damaged cells may lead to complement-mediated exacerbation of tissue injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Heuristics may lead to bias or predictable and systematic cognitive errors, as described in Table 2.16,35”
From Artificial Intelligence and Surgical Decision-making. (2020) · cites this paper as [54]
Citations
Cites
PROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
MOLREP: an Automated Program for Molecular Replacement
Vagin, A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,714
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 3,503
Self-citationWHAT IF: A molecular modeling and drug design program
Vriend, G. (1990) · Journal of Molecular Graphics · doi:10.1016/0263-7855(90)80070-v · Cited by 3,469
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Self-citationThe integration of macromolecular diffraction data
Leslie, A. G. W. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905039107 · Cited by 1,341
The physiological structure of human C-reactive protein and its complex with phosphocholine
Thompson, D., Pepys, M. B., & Wood, S. P. (1999) · Structure · doi:10.1016/s0969-2126(99)80023-9 · Cited by 818
Self-citationIntegration of macromolecular diffraction data
Leslie, A. G. W. (2006) · International Tables for Crystallography · doi:10.1107/97809553602060000675 · Cited by 696
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
Pepys, M. B., Herbert, J., Hutchinson, W. L., Tennent, G. A., Lachmann, H. J., Gallimore, J. R., Lovat, L. B., Bartfai, T., Alanine, A., Hertel, C., et al. (2002) · Nature · doi:10.1038/417254a · Cited by 540
Self-citationGriselli, M., Herbert, J., Hutchinson, W. L., Taylor, K. M., Sohail, M., Krausz, T., & Pepys, M. B. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.12.1733 · Cited by 508
Self-citationMeasurement of serum C-reactive protein concentration in myocardial ischaemia and infarction.
de Beer, F. C., Hind, C. R., Fox, K. M., Allan, R. M., Maseri, A., & Pepys, M. B. (1982) · Heart · doi:10.1136/hrt.47.3.239 · Cited by 358
Self-citationBhakdi, S., Torzewski, M., Klouche, M., & Hemmes, M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.10.2348 · Cited by 326
Ledue, T. B., Weiner, D. L., Sipe, J. D., Poulin, S. E., Collins, M. F., & Rifai, N. (1998) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/000456329803500607 · Cited by 321 · cited 1×
“A (12) B (15) C (11) A versus B A versus C B versus C”
BackgroundControl of the Acute Phase Response
Kushner, I., Broder, M. L., & Karp, D. (1978) · Journal of Clinical Investigation · doi:10.1172/jci108932 · Cited by 306
Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia
Mora, A. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg469 · Cited by 196
Self-citationTransgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice
Hirschfield, G. M., Gallimore, J. R., Kahan, M. C., Hutchinson, W. L., Sabin, C. A., Benson, G. M., Dhillon, A. P., Tennent, G. A., & Pepys, M. B. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503202102 · Cited by 192
Self-citationClapp, B. R., Hirschfield, G. M., Storry, C., Gallimore, J. R., Stidwill, R. P., Singer, M., Deanfield, J. E., MacAllister, R. J., Pepys, M. B., Vallance, P., et al. (2005) · Circulation · doi:10.1161/01.cir.0000159336.31613.31 · Cited by 181
Self-citationEda, S., Kaufmann, J., Roos, W., & Pohl, S. (1998) · Journal of Clinical Laboratory Analysis · doi:10.1002/(sici)1098-2825(1998)12:3<137::aid-jcla2>3.0.co;2-6 · Cited by 162
Isolation and characterization of C-reactive protein and serum amyloid P component in the rat.
de Beer, F. C., Baltz, M. L., Munn, E. A., Feinstein, A., Taylor, J., Bruton, C. J., Clamp, J. R., & Pepys, M. B. (1982) · PubMed · Cited by 158
Self-citationTaylor, K. E., Giddings, J. C., & van den Berg, C. W. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000164623.41250.28 · Cited by 158
Gill, R., Kemp, J. A., Sabin, C. A., & Pepys, M. B. (2004) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000136517.61642.99 · Cited by 141
Self-citationPepys, M. B., Hawkins, P. N., Kahan, M., Tennent, G. A., Gallimore, J. R., Graham, D., Sabin, C. A., Zychlinsky, A., & de Diego, J. (2005) · Circulation Research · doi:10.1161/01.res.0000193595.03608.08 · Cited by 137
Self-citationCRP or not CRP? That Is the Question
Pepys, M. B. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000169644.88847.28 · Cited by 100
Self-citationSerum amyloid P component in chronic renal failure and dialysis.
Nelson, S. R., Tennent, G., Sethi, D., Gower, P., Ballardie, F. W., Amatayakul-Chantler, S., & Pepys, M. (1991) · Clinica chimica acta; international journal of clinical chemistry · doi:10.1016/0009-8981(91)90090-y · Cited by 91
Self-citationHawkins, P., Tennent, G., Woo, P., & Pepys, M. (1991) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1991.tb08166.x · Cited by 75
Self-citationMiller, A. A., Megson, I. L., & Gray, G. A. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703528 · Cited by 42
Self-citationGray, G. A., Mickley, E. J., Webb, D. J., & McEwan, P. E. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703503 · Cited by 16
Self-citationDenvir, M. A., Sharif, I., Anderson, T., Webb, D. J., Gray, G. A., & McDicken, W. N. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2004.09.001 · Cited by 6
Self-citation
Cited by
Role of C-Reactive Protein at Sites of Inflammation and Infection
Sproston, N. R., & Ashworth, J. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00754 · Cited by 3,029
“Thus, in addition to therapeutic strategies to inhibit CRP activity (51), more targeted therapies have been proposed for the treatment of CRP-mediated pathologies, including inhibiting mCRP activity (52) or preventing the dissociation of nCRP into mCRP (53).”
BackgroundMechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
“CVD accounts for more than half of the mortality seen in the diabetic population (228, 319), and diabetes equates to an approximately threefold increased risk of myocardial infarction compared with the general population (155).”
BackgroundInfluentialColchicine in Patients with Chronic Coronary Disease
Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., The, S. H. K., Xu, X.-F., Ireland, M. A., Lenderink, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021372 · Cited by 2,299
Systemic manifestations and comorbidities of COPD
Barnes, P. J., & Celli, B. R. (2009) · European Respiratory Journal · doi:10.1183/09031936.00128008 · Cited by 1,820
Regulation of the Inflammatory Response in Cardiac Repair
Frangogiannis, N. G. (2012) · Circulation Research · doi:10.1161/circresaha.111.243162 · Cited by 1,194
Metadata
- Authors
- Pepys, M. B., Hirschfield, G. M., Tennent, G. A., Ruth Gallimore, J., Kahan, M. C., Bellotti, V., Hawkins, P. N., Myers, R. M., Smith, M. D., Polara, A., Cobb, A. J. A., Ley, S. V., Andrew Aquilina, J., Robinson, C. V., Sharif, I., Gray, G. A., Sabin, C. A., Jenvey, M. C., Kolstoe, S. E., Thompson, D., & Wood, S. P.
- Affiliations
- The Royal Free Hospital (GB)
- University of Pavia (IT)
- University of Cambridge (GB)
- University of Edinburgh (GB)
- University of Southampton (GB)
- University of Sussex (GB)
- Corresponding author
- Pepys, Mark B.
- ORCID
- Venue
- Nature
- Published
- 2006-04
- Volume
- 440
- Issue
- 7088
- Pages
- 1217-1221
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2080883999
- Cited by
- 672
- References
- 31
- Citations by year
- 2026: 6 · 2025: 17 · 2024: 19 · 2023: 30 · 2022: 27 · 2021: 28 · 2020: 32 · 2019: 21 · 2018: 23 · 2017: 20 · 2016: 23 · 2015: 16 · 2014: 35 · 2013: 30 · 2012: 40
- FWCI
- 26.49
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- CentAUR (University of Reading) (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Figshare (submittedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- C-reactive protein, acute myocardial infarction, complement activation, cardioprotection, infarct size, neuroprotection, cerebral ischemia, small-molecule drug design, acute phase proteins, inflammation, stroke, drug repurposing
- MeSH terms
- Animals, C-Reactive Protein, Cardiovascular Diseases, Complement System Proteins, Hexanes, Humans, Male, Models, Molecular, Molecular Conformation, Myocardial Infarction, Phosphorylcholine, Drug Design, Rats, Wistar, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.